Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study-Reference-Cited by-同舟云学术

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

Published:2021-07 Issue: Volume:152 Page:223-232
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

O'Shaughnessy Joyce,Sousa Susana,Cruz Josefina,Fallowfield Lesley,Auvinen Päivi,Pulido Catarina^ORCID,Cvetanovic Ana,Wilks Sharon,Ribeiro Leonor,Burotto Mauricio,Klingbiel Dirk^ORCID,Messeri Dimitri,Alexandrou Ari^ORCID,Trask Peter,Fredriksson Judy,Machackova Zuzana,Stamatovic Ljiljana,Korbenfeld Ernesto,Nadal Jorge,Pinczowski Helio,Cruz Felipe J.,Sousa Gustavo,Goncalves Aline C.,Guilgen Gisah,Burotto Mauricio,Jekunen Antti,Auvinen Päivi,Yeo Winne,Cheng Chi K.,Razeq Hikmat A.,Karak Fadi,Farhat Fadi,Huerta Servando C.,Jaime Brizio M.,Feregrino Juan,Castillo-Fernandez Omar,Alcedo Juan C.,Ribeiro Leonor,Dionisio Maria,Sousa Susana,Pulido Catarina,Bujassoum Salha,Bakhraibah Hatoon,Cvetanovic Ana,Stamatovic Ljiljana,Lescure Alvaro R.,Cruz Josefina,Wendt Camilla,Margolin Sara,Björneklett Helena G.,Cairo Michelina,Dakhil Shaker,Le-Lindqwister Nguyet,Ma Ling,McIntyre Kristi J.,O’Shaughnessy Joyce,Vukelja Svetislava J.,Richards Donald,Wilks Sharon,Wallmark John

Funder

F. Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference16 articles.

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer,2020

2. Estimating the benefits of therapy for early stage breast cancer the st gallen international consensus guidelines for the primary therapy of early breast cancer 2019;Burstein;Ann Oncol,2019

3. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Cardoso;Ann Oncol,2019

4. AGO Breast Cancer guidelines v1,2020

5. Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy;Poorter;Eur J Cancer,1996

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients;Drugs & Therapy Perspectives;2023-12

2. Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access;BioDrugs;2023-10-13

3. A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy;The Breast;2023-10

4. IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications;Annals of Oncology;2023-08

5. DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer;Future Oncology;2023-08